Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Receives Day-74 Letter for KP415 NDA
FDA Sets PDUFA Date of March 2, 2021 CELEBRATION, Fla. , May 19, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today confirmed that the Company has received a filing communication from the
Toggle Summary KemPharm Reports First Quarter 2020 Financial Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 5:00 p.m. ET Corporate and Regulatory Highlights: KP415 NDA filing accepted by FDA on May 1, 2020 KemPharm entitled to receive $5 million milestone payment from GPC Announced that Corium, a portfolio company of
Toggle Summary KemPharm to Report First Quarter 2020 Financial Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Tuesday, May 12, 2020 , 5:00 p.m. ET CELEBRATION, Fla. , May 06, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,
Toggle Summary NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital
Corium, GPC’s portfolio company, to lead all commercialization activities for KP415 CELEBRATION, Fla. , May 04, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today confirmed that the U.S.
Toggle Summary KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD
If approved, KemPharm believes that KP415 may address several unmet needs, including earlier onset of action and longer duration of therapeutic effect vs. other available methylphenidate products CELEBRATION, Fla. , March 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Toggle Summary KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results
KP415 NDA Remains on Track for Q1 2020 Submission CELEBRATION, Fla. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided an update on the KP415 NDA and reported its
Toggle Summary Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement
KemPharm’s Common Stock Listing Transfers to The Nasdaq Capital Market Effective Today CELEBRATION, Fla. , Jan. 15, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it
Toggle Summary KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital
Principal and Interest Payments on Outstanding Debt in Principal Amount of $77.7M Pushed to March 31, 2021 ; Expected to Extend Cash Runway to New Maturity Date KemPharm Will Host a Conference Call and Live Audio Webcast with Slide Presentation Today, Wednesday, December 18, 2019 , at 8:30 a.m.
Toggle Summary KemPharm Reports Third Quarter 2019 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  Today, November 14, 2019 , at 5:30 p.m. ET CELEBRATION, Fla. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary
Toggle Summary KemPharm to Report Third Quarter 2019 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, November 14, 2019 , 5:30 p.m. ET CELEBRATION, Fla. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary